RADIUS
SpecialtyRADIUS is a specialty pharmaceutical company focused on Neurology. Key products include BINOSTO.
RADIUS at a Glance
- Strong track record with 100% execution quality across 9 trials
- Fast trial execution (22 months median completion)
RADIUS's Key Drugs
RADIUS's core commercial portfolio centers on TYMLOS, BINOSTO, spanning Neurology — its most strategically important drugs approved in the last 15 years.
RADIUS's Recent FDA Approvals
New NDA/BLA approvals for RADIUS over the last two years — novel drugs only, excluding generics and label supplements.
RADIUS's Therapeutic Areas
RADIUS's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
RADIUS's Top Competitors
RADIUS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
RADIUS Pipeline Snapshot
RADIUS has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 2 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TYMLOS leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 5/5 completed
- • Speed: 22 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges